Cloudbreak Pharma (HKSE:02592) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02592 Cloudbreak Pharma Inc HKSE:02592
11 GF Score
Price HK$1.22
! 2 Warning Signs
View Full Analysis

What is Cloudbreak Pharma Net Margin %?

Cloudbreak Pharma HKSE:02592 +0.83% 11 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Cloudbreak Pharma ranks worse than 105932.1% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Cloudbreak Pharma's Net Income for the six months ended in Dec. 2025 was HK$-566.80 Mil. Cloudbreak Pharma's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Cloudbreak Pharma's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Cloudbreak Pharma's Net Margin % or its related term are showing as below:


HKSE:02592's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.875
* Ranked among companies with meaningful Net Margin % only.

Cloudbreak Pharma  (HKSE:02592) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cloudbreak Pharma Net Margin % Related Terms

Cloudbreak Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Cloudbreak Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cloudbreak Pharma Net Margin % Chart

Cloudbreak Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 -991.30 0.00

Cloudbreak Pharma Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial 0.00 0.00 -470.19 0.00 0.00

HKSE:02592 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Cloudbreak Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cloudbreak Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cloudbreak Pharma's Net Margin % falls into.


HKSE:02592
11GF Score
Cloudbreak Pharma Inc HKSE:02592
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cloudbreak Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cloudbreak Pharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-526.449/0
= %

Cloudbreak Pharma's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-566.8/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Cloudbreak Pharma (HKSE:02592) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is Cloudbreak Pharma's Net Margin % too high?
Cloudbreak Pharma's current Net Margin % is 0.00%. Based on the distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #999999 out of 944 companies for Net Margin %. This places Cloudbreak Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cloudbreak Pharma Business Description

Address 8921 Research Drive, Irvine, CA, USA, 92618
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score

Get the complete analysis for HKSE:02592

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.22
Price